|
DK2279007T3
(en)
|
2008-04-29 |
2016-08-22 |
Ascendis Pharma Growth Disorders Div As |
Pegylated recombinant relations of human growth hormone
|
|
DK2512450T3
(en)
|
2009-12-15 |
2018-04-23 |
Ascendis Pharma Endocrinology Div A/S |
Dry growth hormone composition transiently bound to a polymer carrier
|
|
AU2011254564B2
(en)
|
2010-05-21 |
2014-03-27 |
Xl-Protein Gmbh |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
|
US20140323402A1
(en)
*
|
2011-08-12 |
2014-10-30 |
Ascendis Phama A/S |
Protein Carrier-Linked Prodrugs
|
|
CN104302408B
(zh)
*
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
|
LT2948777T
(lt)
|
2013-01-22 |
2019-09-25 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. |
Baltymai su pasikartojančiais dipeptidais, kaip terapinis taikinys neurodegeneracinių ligų su padidėjusiu heksanukleotidų pasikartojimu atveju
|
|
JP6259209B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
コラーゲン産生促進剤
|
|
JP6259207B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
エラスチン産生促進剤
|
|
JP6259208B2
(ja)
*
|
2013-06-17 |
2018-01-10 |
雪印メグミルク株式会社 |
ヒアルロン酸産生促進剤
|
|
WO2015067791A1
(en)
|
2013-11-11 |
2015-05-14 |
Ascendis Pharma Relaxin Division A/S |
Relaxin prodrugs
|
|
US9618507B2
(en)
|
2014-02-24 |
2017-04-11 |
Betanien Hospital |
Methods of treating rheumatoid arthritis
|
|
EP3113792B1
(en)
|
2014-03-05 |
2018-12-05 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
|
PL228341B1
(pl)
*
|
2014-04-21 |
2018-03-30 |
Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia |
Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
|
|
EP3185881B1
(en)
*
|
2014-08-26 |
2022-03-09 |
Betanien Hospital |
Methods, agents and compositions for treatment of inflammatory conditions
|
|
US10799563B2
(en)
|
2014-11-18 |
2020-10-13 |
Ascendis Pharma Endocrinology Division |
Polymeric hGH prodrugs
|
|
PL3220892T3
(pl)
|
2014-11-21 |
2022-01-31 |
Ascendis Pharma Endocrinology Division A/S |
Postacie dawkowane długo działającego hormonu wzrostu
|
|
ES2784603T3
(es)
|
2015-06-02 |
2020-09-29 |
Novo Nordisk As |
Insulinas con extensiones recombinantes polares
|
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
|
US10789711B2
(en)
*
|
2015-09-09 |
2020-09-29 |
Technische Universiteit Eindhoven |
Imaging of dispersion and velocity of contrast agents
|
|
EP3355931B1
(en)
|
2015-10-01 |
2024-06-26 |
Novo Nordisk A/S |
Protein conjugates
|
|
EP4491735A3
(en)
*
|
2015-10-08 |
2025-04-16 |
The Governors of the University of Alberta |
Hepatitis c virus e1/e2 heterodimers and methods of producing same
|
|
SG11201803958WA
(en)
*
|
2015-12-22 |
2018-07-30 |
Xl Protein Gmbh |
Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
|
|
PL3393496T3
(pl)
|
2015-12-23 |
2024-04-22 |
The Johns Hopkins University |
Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
|
|
US11389511B2
(en)
|
2016-01-08 |
2022-07-19 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with reduced side-effects
|
|
CA3007976C
(en)
|
2016-01-08 |
2023-09-26 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
US11224661B2
(en)
|
2016-01-08 |
2022-01-18 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with increased NEP stability
|
|
NZ743488A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low initial npr-b activity
|
|
EP4162955A1
(en)
|
2016-01-08 |
2023-04-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with carrier attachment at the ring moiety
|
|
US11311604B2
(en)
|
2016-01-08 |
2022-04-26 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low NPR-C binding
|
|
US11078472B2
(en)
|
2016-01-20 |
2021-08-03 |
Merz Pharma Gmbh & Co., Kgaa |
Recombinant clostridial neurotoxins with increased duration of effect
|
|
SMT202400423T1
(it)
|
2016-03-01 |
2024-11-15 |
Ascendis Pharma Bone Diseases As |
Profarmaci di pth
|
|
SG11201805195YA
(en)
|
2016-03-02 |
2018-07-30 |
Merz Pharma Gmbh & Co Kgaa |
Composition comprising botulinum toxin
|
|
WO2017173346A1
(en)
*
|
2016-04-01 |
2017-10-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Par3 mimetic peptides and uses thereof
|
|
AU2017260274A1
(en)
*
|
2016-05-04 |
2018-11-01 |
Navigo Proteins Gmbh |
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
|
WO2018011266A1
(en)
|
2016-07-13 |
2018-01-18 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
NZ751746A
(en)
|
2016-09-29 |
2023-06-30 |
Ascendis Pharma Growth Disorders As |
Combination therapy with controlled-release cnp agonists
|
|
SMT202300124T1
(it)
|
2016-09-29 |
2023-05-12 |
Ascendis Pharma Bone Diseases As |
Composti pth con bassi rapporti picco/valle
|
|
HUE063235T2
(hu)
|
2016-09-29 |
2024-01-28 |
Ascendis Pharma Bone Diseases As |
Adagolási rendszer szabályozott leadású PTH vegyülethez
|
|
HUE070273T2
(hu)
|
2016-09-29 |
2025-05-28 |
Ascendis Pharma Bone Diseases As |
Szabályozott hatóanyag-leadású PTH vegyületek
|
|
US10738338B2
(en)
|
2016-10-18 |
2020-08-11 |
The Research Foundation for the State University |
Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
|
|
WO2018093274A1
(en)
*
|
2016-11-16 |
2018-05-24 |
Auckland Uniservices Limited |
Methods for protein ligation and uses thereof
|
|
JP2020513019A
(ja)
|
2017-04-05 |
2020-04-30 |
ノヴォ ノルディスク アー／エス |
オリゴマー伸長インスリン−Ｆｃコンジュゲート
|
|
WO2018233813A1
(en)
|
2017-06-20 |
2018-12-27 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
EP3418383A1
(en)
|
2017-06-21 |
2018-12-26 |
XL-protein GmbH |
Modified l-asparaginase
|
|
US10174302B1
(en)
*
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
|
FI3642340T3
(fi)
*
|
2017-06-21 |
2024-06-18 |
Jazz Pharmaceuticals Ireland Ltd |
Muunneltu l-asparaginaasi
|
|
JP7224650B2
(ja)
*
|
2017-06-21 |
2023-02-20 |
エクスエル‐プロテイン ゲーエムベーハー |
タンパク質薬物とｐ／ａペプチドとのコンジュゲート
|
|
EP3649143B1
(en)
|
2017-07-06 |
2022-08-31 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
|
EP3483619A1
(en)
*
|
2017-11-13 |
2019-05-15 |
Technische Universität München |
Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
|
|
WO2019101308A1
(en)
*
|
2017-11-22 |
2019-05-31 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant botulinum toxin with increased duration of effect
|
|
US20190184028A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
Targeting with firbronectin type iii like domain molecules
|
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
|
BR112020019639A2
(pt)
|
2018-03-28 |
2021-01-05 |
Ascendis Pharma Oncology Division A/S |
Conjugados de il-2
|
|
US20210008168A1
(en)
|
2018-03-28 |
2021-01-14 |
Ascendis Pharma A/S |
Conjugates
|
|
TWI724392B
(zh)
*
|
2018-04-06 |
2021-04-11 |
美商美國禮來大藥廠 |
生長分化因子15促效劑化合物及其使用方法
|
|
SMT202500272T1
(it)
|
2018-05-18 |
2025-09-12 |
Ascendis Pharma Bone Diseases As |
Dose iniziale di coniugati di pth
|
|
CN112218877B
(zh)
|
2018-08-27 |
2025-07-25 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
CN111153965A
(zh)
*
|
2018-11-07 |
2020-05-15 |
浙江道尔生物科技有限公司 |
用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
|
|
WO2020109978A1
(en)
|
2018-11-26 |
2020-06-04 |
Novartis Ag |
Lpl-gpihbp1 fusion polypeptides
|
|
CA3137395A1
(en)
*
|
2019-01-10 |
2020-07-16 |
Roswell Biotechnologies Inc. |
Conductive synthetic peptides for molecular electronics
|
|
WO2020165087A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of pth conjugates
|
|
CN113423384B
(zh)
|
2019-02-11 |
2024-01-05 |
阿森迪斯药物生长障碍股份有限公司 |
Cnp缀合物的干燥药物制剂
|
|
SG11202108735QA
(en)
|
2019-03-04 |
2021-09-29 |
Ascendis Pharma Endocrinology Div A/S |
Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
|
|
EP3714909A1
(en)
*
|
2019-03-28 |
2020-09-30 |
Industrie Biomediche Insubri S.A. |
Improved bone implant matrix comprising proline-rich peptide and method of preparing the same
|
|
US10784093B1
(en)
*
|
2019-04-04 |
2020-09-22 |
Thermo Finnigan Llc |
Chunking algorithm for processing long scan data from a sequence of mass spectrometry ion images
|
|
US20220304993A1
(en)
|
2019-06-21 |
2022-09-29 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
|
CA3143436A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
|
WO2020254606A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
|
JP2022545917A
(ja)
|
2019-08-27 |
2022-11-01 |
トニックス ファーマ リミテッド |
修飾ｔｆｆ２ポリペプチド
|
|
JP2022553399A
(ja)
|
2019-10-25 |
2022-12-22 |
ジャズ ファーマシューティカルズ アイルランド リミテッド |
組換えｌ－アスパラギナーゼ
|
|
US12139555B2
(en)
|
2019-12-03 |
2024-11-12 |
Rodan & Fields, Llc |
Peptides and compositions for inhibiting hair growth
|
|
IL293450A
(en)
|
2019-12-03 |
2022-07-01 |
Evotec Int Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
AU2020396647A1
(en)
*
|
2019-12-06 |
2022-07-07 |
Ajinomoto Co., Inc. |
Method for producing peptide having physiological activity, and peptide comprising short linker
|
|
AU2020419444A1
(en)
|
2020-01-03 |
2022-06-09 |
Ascendis Pharma A/S |
Conjugates undergoing intramolecular rearrangements
|
|
EP4090357A1
(en)
|
2020-01-13 |
2022-11-23 |
Ascendis Pharma Bone Diseases A/S |
Hypoparathyroidism treatment
|
|
CN113527485B
(zh)
*
|
2020-04-17 |
2024-11-15 |
湖南麦济生物技术股份有限公司 |
抗人白细胞介素-4受体α抗体及其制备方法和应用
|
|
GB202007106D0
(en)
*
|
2020-05-14 |
2020-07-01 |
Ucl Business Plc |
Cyclosporine analogues
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
EP4192508A1
(en)
|
2020-08-05 |
2023-06-14 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
|
|
JP2023543265A
(ja)
|
2020-09-28 |
2023-10-13 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善
|
|
CA3200238A1
(en)
|
2020-12-22 |
2022-06-30 |
Jonas SCHILZ |
Antibodies specific for structurally disordered sequences
|
|
CN112843222B
(zh)
*
|
2021-01-21 |
2023-01-31 |
暨南大学 |
Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
|
|
WO2022207798A1
(en)
|
2021-04-01 |
2022-10-06 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
|
KR20240082355A
(ko)
|
2021-09-22 |
2024-06-10 |
아센디스 파마 본 디지즈 에이/에스 |
장시간 작용형 pth 화합물 치료
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
CA3249311A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
|
|
AU2023279467A1
(en)
|
2022-06-02 |
2025-01-16 |
Ajinomoto Co., Inc. |
Affinity substance, compound, and antibody and their salts
|
|
CN115927347B
(zh)
*
|
2022-10-14 |
2026-01-16 |
杭州佰辰医学检验所有限公司 |
特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
GB202218084D0
(en)
|
2022-12-01 |
2023-01-18 |
Volution Immuno Pharmaceuticals Sa |
Fusion proteins
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
AU2024337275A1
(en)
|
2023-09-04 |
2026-02-19 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025088192A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for the coupling of di(alkyl)amines to polypeptides
|
|
WO2025088193A1
(en)
|
2023-10-27 |
2025-05-01 |
Xl-Protein Gmbh |
Methods for efficient recombinant production of polypeptides
|
|
WO2025233381A1
(en)
|
2024-05-07 |
2025-11-13 |
Technische Universität München, in Vertretung des Freistaates Bayern |
Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
|
|
GB202408081D0
(en)
|
2024-06-06 |
2024-07-24 |
Volution Immuno Pharmaceuticals Sa |
Methods of removing impurities
|